Silver Complexes of Miconazole and Metronidazole: Potential Candidates for Melanoma Treatment.

Melanoma, arguably the deadliest form of skin cancer, is responsible for the majority of skin-cancer-related fatalities. Innovative strategies concentrate on new therapies that avoid the undesirable effects of pharmacological or medical treatment. This article discusses the chemical structures of [(MTZ) 2 AgNO 3 ], [(MTZ) 2 Ag] 2 SO 4 , [Ag(MCZ) 2 NO 3 ], [Ag(MCZ) 2 BF 4 ], [Ag(MCZ) 2 SbF 6 ] and [Ag(MCZ) 2 ClO 4 ] (MTZ-metronidazole; MCZ-miconazole) silver(I) compounds and the possible relationship between the molecules and their cytostatic activity against melanoma cells. Molecular Hirshfeld surface analysis and computational methods were used to examine the possible association between the structure and anticancer activity of the silver(I) complexes and compare the cytotoxicity of the silver(I) complexes of metronidazole and miconazole with that of silver(I) nitrate, cisplatin, metronidazole and miconazole complexes against A375 and BJ cells. Additionally, these preliminary biological studies found the greatest IC 50 values against the A375 line were demonstrated by [Ag(MCZ) 2 NO 3 ] and [(MTZ) 2 AgNO 3 ]. The compound [(MTZ) 2 AgNO 3 ] was three-fold more toxic to the A375 cells than the reference (cisplatin) and 15 times more cytotoxic against the A375 cells than the normal BJ cells. Complexes of metronidazole with Ag(I) are considered biocompatible at a concentration below 50 µmol/L.